BR9609521A - Fator de crescimento de tecido conectivo - Google Patents

Fator de crescimento de tecido conectivo

Info

Publication number
BR9609521A
BR9609521A BR9609521A BR9609521A BR9609521A BR 9609521 A BR9609521 A BR 9609521A BR 9609521 A BR9609521 A BR 9609521A BR 9609521 A BR9609521 A BR 9609521A BR 9609521 A BR9609521 A BR 9609521A
Authority
BR
Brazil
Prior art keywords
ctgf
growth factor
connective tissue
tissue growth
provides
Prior art date
Application number
BR9609521A
Other languages
English (en)
Inventor
Gary R Grotendorst
Douglass M Bradham Jr
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Publication of BR9609521A publication Critical patent/BR9609521A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
BR9609521A 1995-06-02 1996-05-31 Fator de crescimento de tecido conectivo BR9609521A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/459,717 US5770209A (en) 1991-08-30 1995-06-02 Acceleration of wound healing using connective tissue growth factor
PCT/US1996/008140 WO1996038172A1 (en) 1995-06-02 1996-05-31 Connective tissue growth factor

Publications (1)

Publication Number Publication Date
BR9609521A true BR9609521A (pt) 1999-06-15

Family

ID=23825885

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9608558-4A BR9608558A (pt) 1995-06-02 1996-05-31 Processos e usos de fator de crescimento de tecido conjuntivo como um agente de indução
BR9609521A BR9609521A (pt) 1995-06-02 1996-05-31 Fator de crescimento de tecido conectivo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9608558-4A BR9608558A (pt) 1995-06-02 1996-05-31 Processos e usos de fator de crescimento de tecido conjuntivo como um agente de indução

Country Status (11)

Country Link
US (4) US5770209A (pt)
EP (2) EP0831885A4 (pt)
JP (4) JPH11507332A (pt)
CN (2) CN1195295A (pt)
AT (1) ATE464067T1 (pt)
AU (2) AU720268B2 (pt)
BR (2) BR9608558A (pt)
CA (2) CA2222509C (pt)
DE (1) DE69638162D1 (pt)
SG (1) SG108208A1 (pt)
WO (2) WO1996038168A1 (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US7384634B2 (en) 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
US7026299B2 (en) 1994-07-12 2006-04-11 Human Genome Sciences, Inc. Connective tissue growth factor-2
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
AU763649B2 (en) * 1995-06-02 2003-07-31 University Of South Florida Connective tissue growth factor
US7521540B2 (en) * 1996-03-15 2009-04-21 Munin Corporation CYR61 compositions and methods
US6413735B1 (en) 1996-03-15 2002-07-02 Munin Corporation Method of screening for a modulator of angiogenesis
US20090081228A1 (en) * 1996-03-15 2009-03-26 Munin Corporation Cyr61 compositions and methods
US6790606B1 (en) * 1996-03-15 2004-09-14 Munin Corporation Extracellular matrix signaling molecules
ES2246056T3 (es) * 1996-11-08 2006-02-01 Human Genome Sciences, Inc. Factor 3 de crecimiento de tejido conjuntivo.
US20040132987A1 (en) 1996-11-08 2004-07-08 Human Genome Sciences, Inc. Connective tissue growth factor-3
CA2274122C (en) * 1996-12-06 2004-02-17 Osiris Therapeutics, Inc. Improved chondrogenic differentiation of human mesenchymal stem cells
DE19719652A1 (de) * 1997-05-09 1998-12-03 Merckle Gmbh Tissue-Faktor zur Förderung von Wundheilung
JP2001517093A (ja) * 1997-06-19 2001-10-02 インサイト・ファーマスーティカルズ・インコーポレイテッド 成長因子様タンパク質をコードするポリヌクレオチド
WO1998057976A1 (en) * 1997-06-19 1998-12-23 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US5876730A (en) * 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
JP4537507B2 (ja) * 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
EP1043335A4 (en) 1997-12-25 2005-08-31 Japan Tobacco Inc MONOCLONAL ANTIBODY AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND ITS MEDICAL APPLICATIONS
US20070141181A1 (en) * 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
CA2320202C (en) * 1998-02-13 2010-09-14 Nutramax Laboratories, Inc. Agents and methods for protection, treatment and repair of connective tissue
US6451771B1 (en) 1999-02-12 2002-09-17 Nutramax Laboratories, Inc. Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
US6797289B2 (en) * 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
CN1326361A (zh) * 1998-09-08 2001-12-12 亨利福特保健***公司 通过修饰、调节及抑制***生长因子来检查、预防和治疗肾脏疾病的方法
US6348329B1 (en) 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
US6350472B1 (en) * 1998-12-14 2002-02-26 Steinbach, Pylant, And Hermann, L.L.C. Method of treating HIV infection with transdermal gel containing mammalian liver extract
WO2000035936A1 (en) 1998-12-14 2000-06-22 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
KR100704537B1 (ko) * 1999-02-01 2007-04-09 제네틱스 인스티튜트, 엘엘씨 관절 연골의 치유 및 회복을 위한 조성물
CA2366289A1 (en) * 1999-03-25 2000-09-28 Radoje T. Drmanac Solution-based methods and materials for sequence analysis by hybridization
WO2001015729A1 (en) 1999-08-27 2001-03-08 Fibrogen, Inc. Connective tissue growth factor receptor, its agonists and antagonists, and their therapeutic and diagnostic uses
US20060052328A1 (en) * 2000-07-11 2006-03-09 Human Genome Sciences, Inc. Connective tissue growth factor-2
CA2412124A1 (en) * 2000-07-11 2002-01-17 Haodong Li Connective tissue growth factor-2
US6939540B1 (en) 2000-07-31 2005-09-06 Cornell Research Foundation, Inc. Method of enhancing bone density
US6599526B2 (en) * 2000-08-18 2003-07-29 The University Of North Texas Health Science Center At Fort Worth Pericardial anti-adhesion patch
US7125715B2 (en) 2000-11-22 2006-10-24 Astellas Pharma Inc. Nucleic acid encoding a polypeptide promoting type II collagen formation and aggrecan production
AU2002326939A1 (en) * 2001-09-18 2003-04-01 Fibrogen, Inc. Methods of assaying connective tissue growth factor
EP1438067A4 (en) * 2001-09-24 2006-06-14 Verigen Ag AUTOLOGICAL GROWTH FACTOR COCKTAIL COMPOSITION, MANUFACTURING METHOD AND USE
JP4456796B2 (ja) * 2001-09-27 2010-04-28 株式会社林原生物化学研究所 コラーゲン産生増強剤の製造方法とその用途
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
MXPA04005628A (es) * 2001-12-12 2004-12-06 Merck Patent Gmbh Inhibicion de tristetraprolina para proteger al corazon contra lesiones cardiacas.
EP1616568A3 (en) 2002-04-30 2006-06-21 Alcon, Inc GSK-3 inhibitors and CDK inhibitors as anti-glaucoma agents
PL378030A1 (pl) * 2002-04-30 2006-02-20 Alcon, Inc. Czynniki które regulują, hamują lub modulują działanie i/lub wyrażanie czynnika wzrostowego tkanki łącznej (CTGF), jako wyjątkowe środki do obniżania ciśnienia śródgałkowego i leczenia retinopatii jaskrowej/neuropatii nerwu wzrokowego
WO2004099372A2 (en) * 2003-05-01 2004-11-18 University Of Florida Anti-scarring ribozymes and methods
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US20050153395A1 (en) * 2003-09-29 2005-07-14 Children's Hospital Inc. Unique integrin binding site in connective tissue growth factor (CTGF)
US8258105B2 (en) * 2003-10-07 2012-09-04 Isis Pharmaceuticals, Inc. Antisense oligonucleotides optimized for kidney targeting
US20050191653A1 (en) * 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
WO2005077413A1 (en) 2004-02-11 2005-08-25 Fibrogen, Inc. Ctgf as target for the therapy of diabetic nephropathy
CA2565070A1 (en) 2004-04-28 2005-11-24 Fibrogen, Inc. Anti-ctgf agents for the treatment of pancreatic cancer
WO2005120231A1 (en) * 2004-06-08 2005-12-22 Fibrogen, Inc. Connective tissue growth factor regulates intracellular signaling pathways
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
WO2006102333A2 (en) * 2005-03-21 2006-09-28 Alcon Manufacturing, Ltd. Ophthalmic use of agents which inhibit connective tissue growth factor binding and signalling via the trka/p75ntr receptor complex
MX2007013834A (es) 2005-05-05 2008-02-05 Fibrogen Inc Terapias de enfermedades vasculares.
US20110244006A1 (en) * 2007-11-29 2011-10-06 The Trustees Of Columbia University In The City Of New York Microsphere skin treatment
US20100331249A1 (en) * 2008-07-23 2010-12-30 National Taiwan University Pharmaceutical composition for inhibiting peritoneal dissemination
EP3081648A1 (en) 2008-08-25 2016-10-19 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
EP2340310B1 (en) * 2008-09-22 2015-06-03 RXi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
EP2221387A1 (en) * 2009-02-19 2010-08-25 Université de la Méditerranée Fibrosis susceptibility gene and uses thereof
JP5166360B2 (ja) * 2009-06-23 2013-03-21 株式会社島津製作所 マイクロ反応装置を用いた細胞運動評価方法
CN102666587A (zh) 2009-07-02 2012-09-12 菲布罗根有限公司 用于治疗肌营养不良的方法
WO2011056234A1 (en) 2009-11-06 2011-05-12 Fibrogen, Inc. Treatment for radiation-induced disorders
EP3578183B1 (en) 2010-03-24 2021-09-08 Phio Pharmaceuticals Corp. Rna interference in ocular indications
EP2550002B1 (en) 2010-03-24 2019-05-08 Phio Pharmaceuticals Corp. Rna interference in dermal and fibrotic indications
KR101249041B1 (ko) 2010-04-28 2013-03-29 포항공과대학교 산학협력단 결합조직 성장인자를 이용한 약학적 조성물
WO2012061811A2 (en) 2010-11-05 2012-05-10 Fibrogen, Inc. Treatment method for lung remodeling diseases
US9102721B2 (en) 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
JP6177692B2 (ja) 2011-02-02 2017-08-09 エクスカリアード・ファーマシューティカルズ，インク 結合組織増殖因子（ｃｔｇｆ）をターゲティングするアンチセンス化合物を用いた、ケロイドまたは肥厚性瘢痕の治療法
US10150989B2 (en) 2011-08-05 2018-12-11 Universite D'aix Marseille Fibrosis susceptibility IL22RA2 gene and uses thereof
WO2013165590A1 (en) 2012-05-03 2013-11-07 Fibrogen, Inc. Methods for treating idiopathic pulmonary fibrosis
US9631013B2 (en) 2014-01-28 2017-04-25 Fibrogen, Inc. Therapeutic method for pancreatic cancer
US20210395690A1 (en) * 2018-11-08 2021-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anchorage-independent cells and use thereof
US20220324953A1 (en) 2019-06-04 2022-10-13 Jiangsu Hengrui Medicine Co., Ltd. Anti-connective tissue growth factor antibody and application thereof
WO2021067694A1 (en) * 2019-10-03 2021-04-08 CyPhi LLC Method of connective tissue restoration
JP2023129339A (ja) * 2022-03-02 2023-09-14 イーク ビョルン 結合組織損傷の治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1989A (en) 1841-02-20 Stump-extractor
US5356630A (en) * 1989-02-22 1994-10-18 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US5149691A (en) * 1991-03-12 1992-09-22 Creative Biomolecules, Inc. Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone
FR2678283A1 (fr) * 1991-06-25 1992-12-31 Centre Nat Rech Scient Sequences de nucleotides, sequences d'acides amines correspondantes, et leurs applications biologiques.
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
IL105529A0 (en) * 1992-05-01 1993-08-18 Amgen Inc Collagen-containing sponges as drug delivery for proteins

Also Published As

Publication number Publication date
JP2007051150A (ja) 2007-03-01
AU5958296A (en) 1996-12-18
AU5885596A (en) 1996-12-18
US6069006A (en) 2000-05-30
JPH11507332A (ja) 1999-06-29
CN1191491A (zh) 1998-08-26
BR9608558A (pt) 1999-11-30
DE69638162D1 (de) 2010-05-27
CA2222509A1 (en) 1996-12-05
CA2222609A1 (en) 1996-12-05
US6232064B1 (en) 2001-05-15
SG108208A1 (en) 2005-01-28
CA2222509C (en) 2012-12-04
ATE464067T1 (de) 2010-04-15
JP2004132974A (ja) 2004-04-30
US5770209A (en) 1998-06-23
AU720268B2 (en) 2000-05-25
EP0831903A4 (en) 2001-02-28
WO1996038168A1 (en) 1996-12-05
CN1195295A (zh) 1998-10-07
EP0831885A4 (en) 2000-11-29
MX9709294A (es) 1998-08-30
AU722919B2 (en) 2000-08-17
EP0831903A1 (en) 1998-04-01
EP0831885A1 (en) 1998-04-01
EP0831903B1 (en) 2010-04-14
US6150101A (en) 2000-11-21
WO1996038172A1 (en) 1996-12-05
JPH11506449A (ja) 1999-06-08

Similar Documents

Publication Publication Date Title
BR9609521A (pt) Fator de crescimento de tecido conectivo
AU2001294541A1 (en) Mammalian genes; related reagents and methods
DE69836630D1 (de) Menschliche toll-ähnliche rezeptorproteine, zugehörige reagenzien und verfahren
PT100781A (pt) Sequencias de dna codificadoras de proteinas de superficie externa, proteinas contendo as referidas sequencias, obtidas a partir de borrelia burgdorferi, e vacinas contendo as referidas proteinas
FI961251A (fi) Ihmisten metabotrooppiset glutamaattireseptorialatyypit(HMR4, HMR6, HMR7)ja niihin liittyvät DNA-yhdisteet
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
AU1342888A (en) Molecules comprising at least one peptidic sequence carrying one or a plurality of epitopes characterizing a protein produced by P.Falciparum in hepatocytes and compositions containing them
SE9500023D0 (sv) Method of detecting cancer
EP1908837A3 (en) Human receptor proteins, related reagents and methods
NO20030495L (no) Peptider som presenteres av celler
WO2000042188A3 (en) Interleukin-17 related mammalian cytokines. polynucleotides encoding them. uses
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
BR9713450A (pt) Quimiocinas de mamìfero
WO1998032858A3 (en) Mammalian chemokines; receptors; reagents; uses
AU2818095A (en) Colon specific gene and protein
EP0960937A4 (en) NEW SEMAPHORIN GENE: SEMAPHORIN Y
WO1998031810A3 (en) Mammalian chemokines; receptors; reagents; uses
DE69734199D1 (de) Menschliches netrin-1
EP0780472A3 (en) Stress proteins
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
WO1998041538A3 (en) Novel human cytokine/steroid receptor protein
WO1999019480A3 (en) Human receptor proteins; related reagents and methods
WO2000034335A3 (en) 'death domain' containing receptors
WO1998042868A3 (en) Screening method for proline-rich proteins

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law